Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
NanoVibronix Inc., now ENvue Medical Inc., reports medical-technology developments centered on enteral access, non-invasive therapy and commercialization under the FEED ticker following its completed name and symbol change from NAOV. The company’s ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for assisting clinicians with feeding-tube placement in the gastrointestinal tract, with FDA 510(k) clearance for adult use and real-time bedside visualization.
Recurring updates include ENFit syringe launches and distribution, UroShield® reimbursement and market-access developments, patent activity for feeding-tube navigation and visualization, and commercial leadership changes. The company also describes acoustic-based therapeutic technologies, including PainShield® and UroShield®, that use proprietary low-intensity surface acoustic wave technology for pain, bacterial colonization and biofilm-related applications.
NanoVibronix, Inc. (NASDAQ: NAOV) has successfully closed its public offering of 4,531,434 shares at $0.75 per share, resulting in gross proceeds of approximately $3.4 million. The offering included the underwriter's exercised option for an additional 198,100 shares. The funds will support working capital and facilitate transitioning manufacturing from China to the United States. H.C. Wainwright & Co. was the book-running manager for this transaction, which was conducted under an effective shelf registration statement.
NanoVibronix, Inc. (NASDAQ: NAOV) announced an increase in its public offering to 4,333,334 shares at $0.75 each due to high demand, with expected gross proceeds of approximately $3.25 million. The offering's closing is set for August 27, 2020, pending customary conditions. The underwriter, H.C. Wainwright & Co., holds a 30-day option for an additional 650,000 shares. Proceeds will support working capital and transition manufacturing from China to the U.S. The offering is made under an effective SEC registration statement.
NanoVibronix, Inc. (NASDAQ: NAOV) announced an underwriting agreement with H.C. Wainwright & Co. to sell 3,333,334 shares of common stock at $0.75 per share. The offering, expected to close around August 27, 2020, aims to raise approximately $2.5 million. The proceeds will be allocated for working capital and transitioning manufacturing from China to the United States. Additionally, the underwriter has a 30-day option to purchase up to 500,000 more shares. The offering is registered under Form S-3 with the SEC.
NanoVibronix, Inc. (NASDAQ: NAOV) has commenced shipments of its new UroShield® device to the UK. The company is collaborating with the National Institute of Clinical Evidence (NICE) to prepare for submission for official guidance, aiming to enhance access for NHS patients at risk of catheter-associated urinary tract infections (CAUTI). UroShield® is designed to prevent bacterial colonization in urinary catheters, thus reducing CAUTI rates and associated hospital stays. The company is also pursuing regulatory approvals in Australia and other markets.
NanoVibronix, Inc. (NASDAQ: NAOV) has signed a two-year exclusive distribution agreement with Ultra Pain Products, Inc. for its PainShield™ devices, effective June 22, 2020. This partnership aims to enhance access to opioid-free pain management solutions across the U.S. during the COVID-19 pandemic. The agreement stipulates the distribution of the newest PainShield model under specific pricing and order quantity requirements. The PainShield ultrasound device promises effective pain relief and soft tissue healing, catering to both home and clinical usage.